Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT05549505
What this trial is testing

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Who this might be right for
Breast Cancer
Arvinas Inc. 152
Large-scale testing (Phase 3)Study completedNCT02926196
What this trial is testing

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Who this might be right for
Triple Negative Breast Neoplasms
Istituto Oncologico Veneto IRCCS 474
Testing effectiveness (Phase 2)Study completedNCT01367288
What this trial is testing

Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers

Who this might be right for
Locally Advanced Breast CancerDuctal Histologic TypeWithout Her 2 Overexpression
Hospices Civils de Lyon 53
Not applicableLooking for participantsNCT06894173
What this trial is testing

EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Who this might be right for
Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT02411656
What this trial is testing

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Who this might be right for
EdemaErythemaEstrogen Receptor Negative+6 more
M.D. Anderson Cancer Center 71
Testing effectiveness (Phase 2)Study completedNCT01989780
What this trial is testing

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Japan Breast Cancer Research Group 160
Testing effectiveness (Phase 2)Study completedNCT02593227
What this trial is testing

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Who this might be right for
Breast Cancer
Marker Therapeutics, Inc. 80
Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Not applicableActive Not RecruitingNCT06735742
What this trial is testing

Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 3
Testing effectiveness (Phase 2)Ended earlyNCT02067741
What this trial is testing

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Who this might be right for
Metastatic Breast AdenocarcinomaBreast Cancer
Swiss Cancer Institute 29
Testing effectiveness (Phase 2)Looking for participantsNCT06374459
What this trial is testing

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Who this might be right for
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine 152
Testing effectiveness (Phase 2)Temporarily pausedNCT05656131
What this trial is testing

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
wang shusen 80
Large-scale testing (Phase 3)UnknownNCT02383030
What this trial is testing

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients

Who this might be right for
Metastatic Breast Cancer
Consorzio Oncotech 156
Testing effectiveness (Phase 2)Looking for participantsNCT07492394
What this trial is testing

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Hebei Medical University Fourth Hospital 60
Not applicableStudy completedNCT04498481
What this trial is testing

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Who this might be right for
Breast Cancer
Pfizer 1
Not applicableStudy completedNCT03841266
What this trial is testing

Recurrence Risk Evaluation by 21-gene Detection

Who this might be right for
Relationship and Consistency Analysis
Xijing Hospital 220
Not applicableLooking for participantsNCT06905301
What this trial is testing

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 240
Not applicableUnknownNCT05167643
What this trial is testing

H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study

Who this might be right for
Advanced HR+ HER2 Negative Breast Carcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04225117
What this trial is testing

Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Who this might be right for
Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc. 329
Large-scale testing (Phase 3)Active Not RecruitingNCT02445391
What this trial is testing

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeInvasive Breast Carcinoma+9 more
ECOG-ACRIN Cancer Research Group 415
Next Page